Vandetanib Shows Clinical Benefit When Combined With Docetaxel for Lung Cancer. Combination of targeted agent, chemotherapy improves progression-free survival; therapy inhibits both VEGFR and EGFR. – When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.
Patients who have been exposed to radiation have more aggressive disease and worse clinical outcome than other patients with thyroid cancer. – Patients with thyroid cancer who have previously been exposed to radiation-for example, in the workplace, through environmental exposure or for treatment of acne or another condition-appear to have more aggressive disease and tend to have worse outcomes in the long term, according to a report in the April issue of Archives of Otolaryngology?Head & Neck Surgery, one of the JAMA/Archives journals.